a1d7a36febf8abb653fd0a6808972be4.jpg

Stratasys makes strategic investment in Axial3D Medical

Med-tech startup Axial3D has announced the closing of a $15 million investment round led by a strategic investment of $10 million from Stratasys Ltd. (NASDAQ: SSYS), a leader in polymer 3D printing solutions. This is Stratasys’ first investment in Axial3D. The two companies also will be providing a joint offering to make patient-specific 3D printing solutions for hospitals and medical device manufacturers more accessible so it becomes a mainstream healthcare solution.

Personalized 3D printed anatomic models are used for pre-surgical planning and diagnostic use to improve patient outcomes while shortening the time spent in the operating room. They are also used in education and training, and medical device development. Creating a 3D printed model from a patient’s scan data normally takes several hours and requires a high level of technical expertise and expensive software licenses. Axial3D’s artificial intelligence-powered algorithms enable healthcare providers to segment CT and MRI scans for these models without significant investments in time, specialized skills and large upfront costs.

Stratasys’ J850 Digital Anatomy 3D printer enables medical customers to create models that not only accurately represent the appearance of human tissue but are also biomechanically realistic while suturing, cutting, or inserting and deploying medical devices.

Stratasys is a leading provider of 3D printers, materials and software for these anatomic models. The company’s J850 Digital Anatomy 3D printer enables medical customers to create models that not only accurately represent the appearance of human tissue but are also biomechanically realistic while suturing, cutting, or inserting and deploying medical devices. A range of Stratasys printers and materials have been validated and FDA 510(k) cleared with Axial3D software to produce anatomic models for pre-operative surgical planning and diagnostic use across multiple specialties.

Manufacturing on Demand

Fast turnaround, low cost, comprehensive optimized strategy… FacFox is your one-stop partner for product manufacturing!

Get Quote

“We are proud to be partnering with Stratasys, and have always believed in their technology and, more importantly, their vision for 3D printing in healthcare,” said Axial3D CEO Roger Johnston. “We believe that to move the industry from early adopters to the mainstream, we need to improve the accessibility of models for healthcare so hospitals and medical device manufacturers can scale their patient-specific programs. Our joint offerings will be the positive, disruptive catalyst that medical 3D printing needs to address 3D printing accessibility.”

Stratasys has estimated the opportunity for medical 3D printing at approximately $2.8 billion.

“Many of the world’s leading hospitals are already benefiting from our MediJet and Digital Anatomy 3D printers for medical models,” said Dr. Yoav Zeif, CEO of Stratasys. “We believe that by working together with Axial3D, we can remove the barriers to entry for the remaining majority of hospitals in many countries around the world, dramatically growing the use of 3D printing in pre-surgical planning so it is truly a standard part of patient care. This is about providing a complete tailored solution for customers that is fast, automated and scalable.”

 

You might also like:

Carbon’s bioabsorbable elastomer shows biocompatibility in vivo: The Silicon-Valley based company has made a name for itself as a manufacturer of high-speed photopolymerization 3D printers using durable, reactive materials. The range of Carbon supported resins has continued to increase and now includes more sustainable, up to 40% plant-based materials. This, however is the first biocompatible material for implantation. The developmental bioabsorbable elastomer has reportedly shown impressive mechanical performance, biocompatibility,  and tunability. This includes an absorption rate that can be tuned to suit a variety of potential applications, making it versatile for a broad array of medical uses. Additionally, current in vivo studies have demonstrated the required tissue tolerance and desirable healing responses for an implantable device through 26 weeks.

* This article is reprinted from 3D Printing Media Network. If you are involved in infringement, please contact us to delete it.

Author: 3D Printing Media Network

Leave A Comment

Your email address will not be published. Required fields are marked *